Table 1. Anti-uPAR- and anti-PAI-1 immunoreactions in 60 cases of DCIS (a) and 12 cases of normal (nontumour) breast tissue (b).
| Anti-uPAR IID7 | Anti-uPAR HU277 | Anti-uPAR 3936 | Anti-PAI-1 | |
|---|---|---|---|---|
| (a) DCIS, n=60a | ||||
| Myoepithelial cells | 56 (18/14/24) | 41 (15/12/14) | 39 (14/11/14) | 34 (2/8/24) |
| Tumour cells | 56 (18/14/24) | 50 (15/15/20) | 31 (11/10/10) | 56 (19/14/23) |
| Macrophages | 60 | 60 | 60 | 60 |
| Fibroblasts | 60 | 60 | 60 | 60 |
| Endothelial cells | 56 (17/16/23) | 38 (14/10/14) | 0 | 60 |
| (b) Normal breast tissue, n=12b | ||||
| Myoepithelial cells | 10 | 8 | 5 | 1 |
| Epithelial cells | 10 | 7 | 4 | 1 |
| Macrophages | 12 | 12 | 12 | 12 |
| Fibroblasts | 12 | 12 | 12 | 12 |
| Endothelial cells | 7 | 4 | 0 | 12 |
uPAR=urokinase plasminogen activator receptor; PAI-1=plasminogen activator inhibitor; DCIS=ductal carcinoma in situ. For anti-uPAR immunoreaction three different antibodies were used: mAb IID7, pAb HU277 and mAb 3936.
a
The VNs Classification for DCIS (n=60) was used in this study: group I (VN G1, n=20) consisted of non-high-grade DCIS without comedo-type necrosis; group II (VN G2, n=16) of non-high-grade DCIS with necrosis; and group III (VN G3, n=24) of high-grade DCIS, irrespective of comedo-type necrosis. Behind the number of positive cases the results of group I, -II and III are given within parantheses (group I/group II/group III).
b
Immunohistological results of 12 cases with normal (nontumour) breast tissue.